Table 4.

Common and serious adverse events reported in PARP inhibitor trials [69–71]

	SOLO-1 trial—olaparib group		PRIMA trial—niraparib group		VELIA trial—veliparib throughout group
Event	Any grade (% of patients)	Grade 3 or 4 (% of patients)	Any grade (% of patients)	Grade 3 or 4 (% of patients)	Any grade (% of patients)	Grade 3 or 4 (% of patients)
Anaemia	39	22	63	31	64	38
Neutropenia	23	9	26	12	75	58
Thrombocytopenia	11	1	46	29	58	28
Nausea	77	1	57	1	80	8
Fatigue	63	4	35	2	69	8
Pneumonitis	2	N/A	0	N/A	0	N/A
Acute myeloid leukaemia	1	N/A	0	N/A	0.3	N/A
Myelodysplatic syndrome	0	N/A	0.2	N/A	0*	N/A

*There was an incidence of myelodysplastic syndrome in 1 patient (0.2%) in veliparib combination only group in this trial [71]